Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chiang Mai Ram Medical Business PCLBKK:CMR-R +0.78%36 3-Year EBITDA Growth Rate is 29.30% as of Jun. 2026, which is 190% above its 10-year median of 10.10. GuruFocus rates BKK:CMR-R with a GF Score™ of 36/100 and a GF Value™ of ฿0.55 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Chiang Mai Ram Medical Business PCL ranks better than 77.82% on this metric.
During the past 12 months, Chiang Mai Ram Medical Business PCL's average EBITDA Per Share Growth Rate was 853.30% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 29.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 18.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 4.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Chiang Mai Ram Medical Business PCL was 32.80% per year. The lowest was -14.80% per year. And the median was 10.10% per year.
Chiang Mai Ram Medical Business PCL (BKK:CMR-R) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Chiang Mai Ram Medical Business PCL 3-Year EBITDA Growth Rate Related Terms
BKK:CMR-R vs HCA, THC, EHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Care Facilities subindustry, Chiang Mai Ram Medical Business PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chiang Mai Ram Medical Business PCL 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Chiang Mai Ram Medical Business PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Chiang Mai Ram Medical Business PCL's 3-Year EBITDA Growth Rate falls into.
Chiang Mai Ram Medical Business PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 29.30% mean?
Chiang Mai Ram Medical Business PCL (BKK:CMR-R) has a 3-Year EBITDA Growth Rate of 29.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chiang Mai Ram Medical Business PCL and its competitors. This is 190% above median its historical median of 10.10. According to the industry distribution chart, Chiang Mai Ram Medical Business PCL ranks #116 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 22.2%.
Is Chiang Mai Ram Medical Business PCL's 3-Year EBITDA Growth Rate too high?
Chiang Mai Ram Medical Business PCL's current 3-Year EBITDA Growth Rate of 29.30% is 190% above median its 10-year median of 10.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 9.90. Chiang Mai Ram Medical Business PCL's value of 29.30% is 196% above this industry median. Based on the distribution chart, Chiang Mai Ram Medical Business PCL ranks #116 out of 523 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Chiang Mai Ram Medical Business PCL has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chiang Mai Ram Medical Business PCL's 3-Year EBITDA Growth Rate compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Chiang Mai Ram Medical Business PCL ranks #116 out of 523 companies for 3-Year EBITDA Growth Rate. This places Chiang Mai Ram Medical Business PCL in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 9.90. Chiang Mai Ram Medical Business PCL's value of 29.30% is 196% above this benchmark. While the company's 10-year median is 10.10 vs. the industry median of 9.90, Chiang Mai Ram Medical Business PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 9.90, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chiang Mai Ram Medical Business PCL's current 3-Year EBITDA Growth Rate of 29.30% is 196% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Chiang Mai Ram Medical Business PCL and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chiang Mai Ram Medical Business PCL's current 3-Year EBITDA Growth Rate is 29.30%, which is 190% above median its own 10-year median of 10.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiang Mai Ram Medical Business PCL stock overvalued right now?
Based on GuruFocus' analysis, Chiang Mai Ram Medical Business PCL (BKK:CMR-R) is currently considered Significantly Overvalued. The stock's GF Value™ is ฿0.55, compared to a current price of ฿1.30 — trading 136.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 29.30%, which is 190% above median its 10-year median of 10.10 and 196% above the Healthcare Providers & Services industry median of 9.90. Chiang Mai Ram Medical Business PCL's overall GF Score™ is 36/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Chiang Mai Ram Medical Business PCL (BKK:CMR-R), the current 3-Year EBITDA Growth Rate is 29.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chiang Mai Ram Medical Business PCL (BKK:CMR-R) Overvalued in 2026?
Based on GuruFocus' analysis, Chiang Mai Ram Medical Business PCL stock appears to be overvalued.
The current stock price of ฿1.30 is trading 136.4% above its estimated GF Value™ of ฿0.55.
GuruFocus considers Chiang Mai Ram Medical Business PCL to be Significantly Overvalued.
Key valuation signals for BKK:CMR-R:
3-Year EBITDA Growth Rate: 29.30% (190% above median its 10-year median of 10.10)
GF Value™: ฿0.55 vs. price of ฿1.30 (136.4% above fair value)
Industry Position: 196% above the Healthcare Providers & Services median (#116 of 523)
No single metric tells the full story. See the BKK:CMR-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chiang Mai Ram Medical Business PCL is a Thailand-based company. It provides medical services in the nature of General Hospital, Hospital in Social Security, and the national health security office systems. It offers various medical services including a Dental center, X-ray mobile for a checkup, CT Multislice, Cardiac Catheterization Center, Back pain center, Gynecologic Cancer center, Physical therapy, Operating theatres, Laboratory, Ambulance Services, and Health checkup center, and others. The company provides medical services through the Lanna Hospital.
36GF Score
Get the complete analysis for BKK:CMR-R
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:CMR-R has been successfully added to your 
